Comparative Pharmacology
Head-to-head clinical analysis: LIMBITROL versus LORAZEPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIMBITROL versus LORAZEPAM.
LIMBITROL vs LORAZEPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Limbitrol is a combination of chlordiazepoxide (a benzodiazepine) and amitriptyline (a tricyclic antidepressant). Chlordiazepoxide enhances GABA-A receptor activity, producing anxiolytic and sedative effects. Amitriptyline inhibits serotonin and norepinephrine reuptake, elevating mood and reducing pain. The combination is used for depression with anxiety.
Benzodiazepine that enhances GABA-A receptor activity by increasing frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
1-2 tablets (5 mg chlordiazepoxide / 12.5 mg amitriptyline per tablet) orally 3-4 times daily. Maximum 6 tablets per day in divided doses.
2-3 mg orally or IV, 3-4 times daily; maximum 10 mg/day. For anxiety, 0.5-2 mg orally 2-3 times daily. For procedural sedation, IV: 0.044 mg/kg or 2 mg total, may repeat.
None Documented
None Documented
Clinical Note
moderateLorazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Lorazepam is combined with Fluticasone propionate."
Clinical Note
moderateLorazepam + Haloperidol
"The risk or severity of adverse effects can be increased when Lorazepam is combined with Haloperidol."
Clinical Note
moderateLorazepam + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Lorazepam."
Clinical Note
moderateLorazepam + Clemastine
Amitriptyline: 20-30 hours (range 10-46 h) with a terminal elimination half-life of ~24 h; clinical significance requires 7-14 days to reach steady state. Chlordiazepoxide: 5-30 hours (up to 48 h for active metabolite desmethylchlordiazepoxide).
Terminal elimination half-life is 12-18 hours. Clinically significant for once-daily dosing; may accumulate in elderly or hepatic impairment.
Renal (approximately 70-80% as metabolites, 1-3% unchanged) and fecal (20-30% via biliary elimination for chlordiazepoxide component; amitriptyline is primarily excreted renally as metabolites, 10-15% unchanged).
Primarily renal excretion as glucuronide conjugates; less than 1% excreted unchanged. Approximately 60-80% eliminated in urine, with 15-20% in feces.
Category C
Category D/X
Benzodiazepine/Tricyclic Antidepressant Combination
Benzodiazepine
"The risk or severity of adverse effects can be increased when Lorazepam is combined with Clemastine."